clinical trial · NCT05414500
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
University of Alabama at Birmingham·phase1·recruiting·n = 10
Cutaneous T Cell LymphomaMycosis FungoidesMogamulizumabBrentuximab vedotin
brief summary
This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab. The primary objective of the study is to assess the safety and tolerability of the combination. The primary objective is also to explore safe dose of combination for future expansion.
started
May 1, 2023
primary completion
Apr 30, 2026
completion
Jul 31, 2026
last updated
Apr 9, 2026
official title
Phase I Study of Mogamulizumab (M) in Combination With Brentuximab Vedotin (BV) in Previously Treated Cutaneous T Cell Lymphoma (CTCL) and Mycosis Fungoides (MF)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol